Pre-assessment of pharmacological immunosuppression in Rheumatology
DOI:
https://doi.org/10.51481/amc.v59i4.980Keywords:
Biological agents, immunosuppression, protocols, rheumatic disease, treatment, prophylaxisAbstract
In the last 15 years therapies and therapeutic schemes have been developed to induce remission to the vast majority of rheumatologic diseases. The clinical improvement achieved is at the cost of a more aggressive and specific immunosuppression, which leads to an increase in the risk of infections. The main cause of death of autoimmune diseases in the first 5 years of evolution is infection secondary to immunosuppression. The objective of the present study was to develop a consensus document with the aim of reducing this risk of infection, based on the best available medical evidence, using the resources available in our hospital to reduce the morbidity and mortality of patients receiving these therapies. Having a consensus document will allow us to minimize side effects and improve therapeutic action with greater opportunities for referral and better utilization of institutional resources.
Downloads
References
Gomez-Reino J, Carmona L, M. Descalzo M.A. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-761.
Carmona L, Descalzo MA, Ruiz-Montesinos D, Manero-Ruiz FJ, et al. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0 Rheumatology 2011; 50: 8592.
Carmona L, Gómez-Reino J, González-González R. Registro español de acontecimientos adversos de terapias biológicas en enfermedades reumáticas (BIOBADASER): informe de la situación a 14 de enero 2005. Reumatol Clin 2005; 1:95-111.
Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301: 737-744.
Smolen JS, Beaulieu A., Rubbert-Roth A., Ramos-Remus C, et al. Effect of interleukin-6 receptor inhibition with Tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-997.
Solomon DH. The comparative safety and effectiveness of TNF-alpha antagonists. JMCP 2007; 13 (1 Suppl): S7-S18.
Keane J, Gershon S, Wise RP, Mirabile-Levens E, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-1104.
Geborek P, Bladstrom A, Turesson C, Gulfe A, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699-703.
Okada SK, Siegel JN. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 2006; 296: 2201-2202.
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285.
Setoguchi S, Schneeweiss S, Avorn J, Katz JN, et al. Tumor necrosis factor-alpha antagonist use heart failure in elderly patients with rheumatoid arthritis. Am Heart J 2008: 156; 336-341.
Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatmentnaive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315 - 322
Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving Adalimumab. J Rheumatol 2007; 34: 272-279
Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, et al. Vaccination against influenza in patients with rheumatoid arthritis: The effect of rituximab on the humoral response. Ann Rheum Dis 2008; 67: 937-941
Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 2005; 35: 112-121.
Roll P, Rubbert-Roth A, Tony HP. [Tocilizumab. What comes after TNF-blockers in clinical routine?] Z Rheumatol 2010; 69: 608-617.
Keystone EC. Safety of biologic therapies-an update. J Rheumatol 2005; 74: 8-12.
Gómez-Reino J, Lozab E, Andreuc JL, Balsa A. Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas. Reumatol Clin 2011; 7: 284 - 298.
Downloads
Published
Versions
- 2017-11-20 (2)
- 2017-11-20 (1)
Issue
Section
License
Copyright (c) 2017 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
